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Introduction
Brca1 appears to have a role in multiple complex biologi-
cal pathways including DNA damage repair, transcrip-
tional regulation, and cell-cycle checkpoint control. Brca1
is thought to function as a caretaker that is responsible for
maintaining genomic integrity [1]. Loss of Brca1 function
has been shown to lead to defective DNA repair, to defec-
tive G2-M cell-cycle checkpoints, to increased apoptosis,
and to genomic instability. This generalized genetic insta-
bility is thought to lead to the accumulation of additional
mutations that eventually allow Brca1-deficient cells to
undergo neoplastic transformation (reviewed in [2]).
Perhaps the most intriguing role of Brca1, however, is its
complex interaction with Trp53.
The recent study by Xu et al. attempts to clarify our under-
standing of the complicated Trp53/Brca1 relationship [3].
Substantial evidence suggests that Brca1  and  Trp53
appear to be linked in their roles as tumor suppressor
genes.  Brca1  and  Trp53  are coordinately regulated in
their gene expression [4]. Brca1  physically associates
with Trp53 and stimulates its transcriptional activity [5,6].
The Trp53 protein appears to regulate Brca1 expression
levels [7], while Brca1 in turn upregulates p21 [8]. Brca1
loss therefore triggers the Trp53-Cdkn1a-mediated cell-
cycle checkpoint and corresponding cell death [9]. Finally,
Trp53 loss appears to enhance Brca1-linked tumorigenesis
[10–12].
Trp53 rescue of Brca1 embryonic lethality
The specific role of Trp53 in rescue of embryonic lethality
of mice with various Brca1  mutations remains unclear.
Earlier studies have shown that Trp53 and Cdkn1a defi-
ciencies can extend the development of several severe
Brca1 mutations [13–15]. Xu et al. [3] found that haploid
loss of Trp53 significantly rescues the embryonic lethality
resulting from a Brca1∆11/∆11 mutation. These Brca1∆11/∆11
embryos normally die during late gestation in a wild-type
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Trp53 background. With p53 haploinsufficiency, however,
approximately 80% of the expected Brca1∆11/∆11Trp53+/–
mice survive based on Mendelian ratios for offspring from
a double heterozygous cross. Unfortunately, Xu et al. [3]
failed to note that the Brca1 and Trp53 loci reside within
20 cM of each other on mouse chromosome 11. These
loci are therefore closely linked and do not recombine
independently, as they would if located on different chro-
mosomes. To determine the predicted genotypic distribu-
tion of offspring, the phase of the mutant Brca1 and
Trp53 alleles on the parental chromosomes used in this
intercross must be known. The expected numbers of spe-
cific genotypes in the offspring will differ widely depend-
ing on whether the mutant Brca1 and Trp53 alleles were
present in cis versus trans configurations in the parental
chromosomes.
Two other groups have described mice with related hypo-
morphic mutant Brca1 alleles that remove all or part of
exon 11 while preserving the ∆11 exon splice variant that
produces a truncated Brca1 protein. Cressman et al. [16]
described three mice homozygous for both a mutant
Trp53 and a Brca1 alteration that normally results in late
embryonic lethality in the homozygous state. These
authors propose that other genetic factors in addition to
Trp53 loss may be required for the survival of these
Brca1-mutant mice. It is interesting to speculate that
DBA/2-specific alleles may be involved since the DBA/2
genetic background also appears to enhance survival of
hypomorphic Brca2 mutants [17,18].
Ludwig et al. have generated mice with a related hypomor-
phic Brca1 mutation [19], which was viable in particular
genetic backgrounds in the absence of any additional
Trp53 mutation. This exon 11 mutation was predicted to
lead to the truncation of the Brca1 protein after the first
924 amino acids. This mutant Brca1 protein is unique
since it retains the nuclear localization signals in exon 11
as well as a proposed Trp53 interaction domain between
residues 224 and 500 [2,5]. However, a ∆11 splice
variant protein is also still expressed in these mice as with
mutants from the other groups. From original intercrosses
between 129/Sv × C57BL/6J heterozygous parents,
Ludwig et al. found only 4% homozygous Brca1 mutants
compared with the expected 25%. After backcrossing
with 129/Sv mice or outcrossing to the MF1 strain,
however, these investigators reported complete restora-
tion of Mendelian ratios. These Brca1 mutant mice thus
appeared to have a more complete rescue of embryonic
lethality based on genetic background differences alone
than Xu et al. were able to obtain by introducing Trp53
haploinsufficiency. Unfortunately, Xu et al. did not provide
any information about the genetic background of their
mutant mice. This dramatic difference in explanations for
the embryonic lethality ‘rescue’ of these similar Brca1
mutations is difficult to reconcile.
Xu et al. state that a major finding of the study was the
ability to demonstrate the widespread apoptosis of Brca1-
deficient embryos and the lack of this apoptosis in the
Brca1 mutants with Trp53 mutations [3]. They propose that
the apoptotic process normally triggered by Brca1 loss
does not occur with Trp53 haploinsufficiency due to loss of
the critical G1-S checkpoint control. Cells with Brca1 muta-
tions that have accumulated DNA damage are therefore
allowed to proliferate rather than undergo apoptosis. Xu et
al. suggest this difference in apoptosis is a plausible expla-
nation for the rescue of the embryonic lethality of these
Brca1  mutants. However, the rescue of Brca1∆11/∆11
embryos did not occur when single downstream pathways
of p53 were disrupted by eliminating either Bax or Cdkn1a.
Mammary tumorigenesis association with
combined Trp53/Brca1 deficiency
Multiple studies have now suggested that Trp53 loss
accelerates mammary tumor formation when associated
with Brca1 mutations. Although quantitative data was not
presented in this report, Xu et al. [3] state that most of
their female Brca1∆11/∆11 mice that carried a Trp53 muta-
tion developed mammary tumors with loss of the remain-
ing Trp53 allele by 6–12 months of age. Ludwig et al. [13]
found that many of their homozygous Brca1-mutant mice
also developed mammary tumors as well as a wide variety
of other tumors. They also investigated whether Trp53
deficiency affected this Brca1-associated tumorigenesis,
and observed accelerated tumorigenesis in mice carrying
both mutations.
Trp53 hemizygosity allowed mice with the Brca1 mutation
developed by Cressman et al. [11] to develop a few
mammary tumors after exposure to ionizing radiation,
although these results did not achieve statistical signifi-
cance. In contrast, mice with this Brca1  mutation on a
wild-type  Trp53  background did not develop mammary
tumors. Finally, there was a decreased latency and
increased incidence of mammary tumor formation in condi-
tionally mutant Brca1  mice that had a Trp53 mutation
[12,20]. A high frequency of Trp53 mutations has also
been observed in human BRCA-linked tumors. Some of
these Trp53 mutations are unique or unusual, suggesting
that the tumorigenesis pathway mediated by combined
Brca1/Trp53 mutations may be different to the pathway
for other Trp53-mediated tumorigenesis, such as what is
observed in Li–Fraumini syndrome [21,22].
Biological pathway of the Trp53/Brca1
interaction
Xu et al. attempted to further elucidate the molecular inter-
action between Trp53  and  Brca1  that might lead to
tumorigenesis in the Brca1∆11/∆11 mice [3]. Trp53 was
found to have decreased stability in the Brca1∆11/∆11 back-
ground after treatment with exogenous DNA damaging
agents. Increased Mdm2 levels and decreased phospho-Breast Cancer Research    Vol 4 No 2 McAllister and Wiseman
rylation of Trp53  at Ser18 in γ-irradiated  Brca1∆11/∆11
mutant cells were suggested to be the primary causes for
the decreased stability of Trp53 in these cells. Xu et al.
propose that this decreased stability of Trp53 after stress-
induced DNA damage might allow additional mutations to
accumulate. Ultimately, such genetic alterations may allow
the proliferation defect of Brca1 deficiency to be over-
come, and Brca1-associated tumorigenesis will result.
Conclusions
Although the report by Xu et al. has contributed to our
understanding of the Brca1/Trp53 relationship, a number
of key questions remain to be addressed.
Why a rescue of Brca1-deficient embryonic lethality
with Trp53?
The authors propose the substantial difference found in
apoptosis between Brca1∆11/∆11  mutant cells with or
without Trp53  mutations is a logical explanation for the
rescue of the embryonic lethality of these Brca1 mutants.
However, several studies suggest that Brca1 mutant
embryos in which the Trp53-mediated apoptotic pathway
is intact do not necessarily have an increase in apoptosis
[14,16]. In addition, the rescue of Brca1∆11/∆11 embryos
did not occur when disrupting single downstream path-
ways of Trp53. This suggests that the process through
which Trp53  might allow for an extension of survival of
Brca1 mutants must involve either multiple Trp53-medi-
ated pathways or additional genetic pathways altogether.
What is the relationship between BRCA1 and Trp53
mutations that leads specifically to mammary tumor
development?
The basis for the tissue specificity for Brca1/Trp53 tumori-
genesis remains unknown. It is interesting that the inci-
dence of mammary tumors in Trp53-deficient mice
appears to be dependent on genetic background strain
[23]. This suggests that different sets of modifier loci in
different inbred strains of mice impact the effect of the
loss of Trp53  in specific cell types or tissues. Other
studies have shown that the type of tumor resulting from
Trp53 loss can differ dramatically depending on the tissue
type and the oncogenic pathway involved [2]. In mammary
tumorigenesis, it has been suggested that BRCA1 and
Trp53  deficiencies cooperate only with exposure of the
mammary gland to DNA damage [11]. Alternatively, a lack
of downstream mediators in tissues other than ovarian and
mammary glands has been suggested to explain the
tissue-specificity of Brca1-associated tumorigenesis [2].
Are the molecular mechanisms for the Trp53 rescue of
Brca1 embryonic lethality and the Trp53-mediated
acceleration of Brca1-induced mammary tumorigenesis
the same?
Even if one assumes that Trp53-mediated apoptosis is
significantly relevant for the mechanism of Trp53 rescue of
Brca1 lethality, it is unclear how this Trp53 mechanism
relates to tumorigenesis due to Trp53 loss. Although
some studies clearly demonstrate the association of loss
of  Trp53  with loss of apoptosis in developing tumors,
other studies do not find this correlation, suggesting that
p53 loss might alter tumor progression by different mech-
anisms in different cell types or tumor pathways [24,25]. In
fact, some evidence suggests that the multiple functions
of Trp53 as a tumor suppressor, apoptosis inducer, and
cell-cycle regulator may be entirely independent from each
other [26]. Future directions to begin to establish the
downstream partners and pathways involved in
Brca1/Trp53 tumorigenesis will clearly be necessary to
answer these questions.
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